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Marine organisms have developed strategies to cope with specialised environmental conditions. One common strategy is the production of biosurfactant
compounds to access specific nutrients, promote biofilm development and as act defence against pathogenic microorganisms. The MARISURF consortium
phenotypically screened over 600 marine bacterial strains for biosurfactant production, resulting in the identification of 7 strains of interest. Here we present the
characterisation of biosurfactants produced by one of these marine strains: Marinobacter sp. MCTG107b. We also present an investigation of the antibiofilm
properties of biosurfactants produced by a second strain, Halomonas sp. TGOS10, against known human pathogens.
Two marine bacterial strains, TGOS-10 and MCTG107b were investigated for
biosurfactant production. BLASTn analysis of partial 16S rRNA gene
sequences amplified from these strains showed >99% similarity to the genus
Halomonas and Marinobacter, respectively. Strains TGOS-10 and MCTG107b
significantly reduced the surface tension of the culture supernatant to 29.0
mNm-1 and 31.0 mNm-1 respectively, Fig 1.
The antibiofilm properties of biosurfactants derived from Halomonas sp.
TGOS-10 against pathogenic microorganisms were investigated. The growth
of P. aeruginosa PAO1 was inhibited by 45% and growth of S. aureus ATCC
9144 was inhibited by 100% during co-incubation for 24h with biosurfactant
at a concentration of 1.0 mgmL-1, Fig 3.
Fig. 1 CFU and surface tension reduction kinetics of Halomonas TGOS-10 (A) and
Marinobacter sp. MCTG107b (B). During growth in Zobell marine media using 1% (v/v)
rapeseed oil as a carbon source in a 5 L bioreactor. Surface tension (¨) was seen to reduce
to a stable value within the first 24 h of growth and corresponded with the strain
reaching the stationary growth phase, as measured by viable cell counts (¡).
Fig. 3 Percentage inhibition of biofilms formed of S. aureus ATCC 9144 (A) and P.
aeruginosa PAO1 (B) during co-incubation with biosurfactant-TGOS-10. *** represents a
significant level of inhibition compared to biofilms cultures in the absence of biosurfactant
(n = 3)
Fig. 2 HPLC-MS-MS profile of daughter products resulting from the fragmentation of a
molecular ion, m/z of 651.73, observed in a HPLC-MS analysis to be the predominant
compound fromMarinobacter sp. MCTG107b. The observed products corresponded to the
predicted mol. weights of the fragmentation of di-rhamnolipid Rha-Rha-C10-C10.
Characterisation of the biosurfactants produced by Marinobacter sp.
MCTG107b using both HPLC-MS and tandem MS showed a mixture of 14
different rhamnolipid congeners, Fig 2 & Table 1.
Ongoing work and Conclusions
• Marine-derived biosurfactants are promising compounds for product
development due to their, surface-activity, non-toxicity and anti-
microbial properties combined with sustainable production.
• The biosurfactant produced by Marinobacter sp. MCTG107b was
phenotypically and structurally characterized as rhamnolipids with
varying congeners.
• The biosurfactant produced by Halomonas sp. TGOS-10 showed
antibiofilm activity against pathogenic microorganisms.
• The chemical characterisation of TGOS-10 derived biosurfactant (HPLC-
MS/NMR) is ongoing.
• Marinobacter sp. MCTG 107b was shown to be avirulent in a Galleria
mellonella model, Halomonas sp. TGOS-10 is yet to be tested, however
reports of Halomonas infectious disease in humans are rare.
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Mono-rhamnolipid congeners 
14.8 387.22 Rha-C14:2 386.48 C20H34O7 3.18 
21.5 533.46 Rha-C10-C12 / Rha-C12-C10 532.71 C28H52O9 0.22 
24.2 503.47 Rha-C10-C10:1 502.64 C26H46O9 0.27 
26.9 561.52 Rha-C12-C12/ Rha-C10-C14 560.76 C30H56O9 0.94 
Subtotal 4.61 
Di-rhamnolipid congeners 
4.6 453.27 Rha-Rha-C8 452.49 C20H36O11 1.95 
12.7 480.39 Rha-Rha-C10 480.55 C22H40O11 5.13 
22.1 537.45 Rha-Rha-C14 536.65 C26H48O11 0.21 
31.0 649.71 Rha-Rha-C10-C10:1 / Rha-Rha-C10:1-C10 648.74 C32H56O13 2.85 
32.1 651.73 Rha-Rha-C10-C10 650.79 C34H58O13 52.45 
32.8 677.77 Rha-Rha-C10-C12:1 676.83 C33H60O13 1.06 
33.0 665.77 Rha-Rha-C10-C10-CH3 664.82 C42H60O13 23.07 
34.5 803.54 Decenoyl-Rha-Rha-C10-C10:1 801.01 C35H72O11 0.40 
35.1 679.78 Rha-Rha-C10-C12 / Rha-Rha-C12-C10 678.84 C35H64O13 5.01 
37.2 693.90 Rha-Rha-C10-C12-CH3 / Rha-Rha-C12-C10-CH3 692.80 C35H64O13 3.26 
Subtotal 95.39 
 
Biosurfactant-TGOS-10 effectively inhibited biofilms of S. aureus. Scanning
electron microscopy revealed potential damage to the the EPS matrix of the
biofilm, Fig 4. Due to the increasing problem of inhibiting biofilm associated
pathogenic bacteria with conventional antibiotics, marine biosurfactants can
be a promising alternative or additive for treating these infections.
Fig. 4 Images of S. aureus biofilm grown in the absence and presence of 1.0 mgmL-1
biosurfactant-TGOS-10 observed at 3000x (A,B) and 24000x (C,D).
Table. 1 List of rhamnolipid congeners synthesised by Marinobacter sp. MCTG107b.
Rhamnolipid congeners were identified via HPLC-MS in SPE purified extracts from cell-
free culture supernatant samples obtained after 96 h growth in a 5 L bioreactor.
